Insights

Gathering insights about MYM…

Similar companies to MYM

MYM Tech Stack

MYM uses 8 technology products and services including Twitter Ads, React, Envoy, and more. Explore MYM's tech stack below.

Twitter Ads
Advertising
React
Javascript Frameworks
Envoy
Load Balancers
PHP
Programming Languages
Pingdom
Real User Monitoring
Cloudflare Bot Management
Security
X-Content-Type-Options
Web & Portal Technology
Twitter
Widgets

Media & News

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
BALTIMORE--(BUSINESS WIRE)---- $MYMD--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, “TNFA,” effective before the market open today, July 24, 2024. The new trading symbol “TNFA” replaces t.
Jul 24, 2024 | www.businesswire.com
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced the appointment of Mitchell Glass, M.D., a member of the board of directors of the Company, as president and chief medical officer. The Company also announced the appointment of Mr. Stephen Friscia, a veteran investor, to the board of.
Jun 17, 2024 | www.businesswire.com
MyMD Pharmaceuticals Secures Strategic Investments
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, PharmaCyte Biotech, Inc. (Nasdaq: PMCB), a clinical-stage biotechnology company developing cellular therapies for can.
May 21, 2024 | www.businesswire.com
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phase 2 clinical trial for its lead product, MYMD-1 in sarcopenia, and is moving its clinical program forw.
May 21, 2024 | www.businesswire.com
Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?
MyMD Pharmaceuticals (NASDAQ: MYMD ) stock is heading higher on Tuesday after announcing a new amendment to a securities purchase agreement with preferred shareholders. MyMD Pharmaceuticals reached an agreement with holders of these securities to delay its March 2024 and April 2024 payments.
Apr 09, 2024 | investorplace.com
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on March 4, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (“Listing Rule”) for.
Mar 05, 2024 | www.businesswire.com
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. Eastern Standard Time on Wednesday, February.
Feb 13, 2024 | www.businesswire.com

MYM's Email Address Formats

MYM uses at least 1 format(s):

MYM Email Formats	Example	Percentage
First@mym.fans	John@mym.fans	61%
First.Last@mym.fans	John.Doe@mym.fans	32%
FirstL@mym.fans	JohnD@mym.fans	5%
FL@mym.fans	JD@mym.fans	2%

Frequently Asked Questions

Where is MYM's headquarters located?

MYM's main headquarters is located at Paris, Île-de-france 75002 France. The company has employees across 6 continents, including EuropeSouth AmericaNorth America.

What is MYM's stock symbol?

MYM is a publicly traded company; the company's stock symbol is MYMK.

What is MYM's official website and social media links?

MYM's official website is mym.fans and has social profiles on LinkedIn.

What is MYM's NAICS code?

MYM's NAICS code is 5191 - Other Information Services.

How many employees does MYM have currently?

As of February 2026, MYM has approximately 488 employees across 6 continents, including EuropeSouth AmericaNorth America. Key team members include Ceo: G. L.Chief People Officer / Drh: O. A.Chief Legal & Public Affairs Officer: P. B.. Explore MYM's employee directory with LeadIQ.

What industry does MYM belong to?

MYM operates in the Social Networking Platforms industry.

What technology does MYM use?

MYM's tech stack includes Twitter AdsReactEnvoyPHPPingdomCloudflare Bot ManagementX-Content-Type-OptionsTwitter.

What is MYM's email format?

MYM's email format typically follows the pattern of First@mym.fans. Find more MYM email formats with LeadIQ.

MYM

Q: What is MYM's official website and social media links?

MYM's official website is mym.fans. MYM has social profiles on LinkedIn.

Q: How many employees does MYM have currently?

MYM has approximately 488 employees.

Q: What technology does MYM use?

MYM's tech stack includes Swiper, AddToAny, RSS, Preact, Mautic.

Social Networking PlatformsÎle-de-france, France201-500 Employees

Started in 2019 by Gaspard Hafner and Pierre Garonnaire, MYM is the first French and European fansite made for creators.

Being part of the MYM adventure means joining a French company on a mission to become the number one fansite in the world for content creators.

A few key numbers about MYM:
- 60 team members (and we're just getting started!)
- 18 million users in 2025
- 167,000 certified creators and artists

The leading fansite in France and Europe for content creators

We offer all our team members a supportive, inclusive, and fulfilling work environment.

We’re hiring—come join us! 👋